Synthetic membrane-receiver complexes

Abstract

Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.

Description

RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 15 / 473,421, filed Mar. 29, 2017, which is a continuation of U.S. patent application Ser. No. 14 / 738,414, filed Jun. 12, 2015, which is a continuation of U.S. patent application Ser. No. 14 / 581,486, filed Dec. 23, 2014, which is a continuation of International Application No. PCT / US2014 / 065304, filed Nov. 12, 2014, entitled “Synthetic Membrane-Receiver Complexes”, which claims the benefit of U.S. Provisional Application No. 61 / 962,867, filed Nov. 18, 2013; U.S. Provisional Application No. 61 / 919,432, filed Dec. 20, 2013; U.S. Provisional Application No. 61 / 973,764, filed Apr. 1, 2014; U.S. Provisional Application No. 61 / 991,319, filed May 9, 2014; U.S. Provisional Application No. 62 / 006,825, filed Jun. 2, 2014; U.S. Provisional Application No. 62 / 006,829, filed Jun. 2, 2014; U.S. Provisional Application No. 62 / 006,832, filed Jun. 2, 2014; U.S. Provisional Application No. 62 / 025,367, filed...

AI Technical Summary

Benefits of technology

[0019]In other embodiments, the method comprises administering the pharmaceutical composition at least twice over a treatment period such that the self-antibody mediated disease, disorder or condition is prevented.

[0285]Aspects of the invention relate to pharmaceutical compositions comprising a population of functional erythroid cells comprising a receiver for use in any of the methods of treatment or prevention described herein. In some embodiments, the receiver polypeptide interacts with a target residing in the circulatory system of the subject. In some embodiments, the presence, absence, elevated or depressed level of the target is associated with a disease, disorder or condition. In some embodiments, interacting with a target comprises binding to the target, degrading the target, cleaving the target, and / or sequestering the target. In some embodiments, the administration of the pharmaceutical compositions comprising a population of functional erythroid cells comprising a receiver results in a substantial reduction of the concentration or number of the target in the circulatory system of the subject.

Problems solved by technology

The efficacy of therapeutic compositions that alleviate or prevent diseases and conditions associated with the circulatory system is often limited by their half-life, which is typically up to a few days.

The activity of therapies is also often limited by an immune reaction elicited against them (see, e.g., Wang et al., Leukemia 2003, 17:1583).

The undesirable effects seriously limit the potential for therapeutic applications of technologies based on erythrocyte ghosts.

However, as hESC-MSCs are not infinitely expansible, large scale production of exosomes would require replenishment of hESC-MSC through derivation from hESCs and incur recurring costs for testing and validation of each new batch (Chen et al.

Clinical translation is also hindered by the lack of suitable and scalable nanotechnologies for the purification and loading of exosomes (Lakhal and Wood 2011 BioEssays 33(10):737).

Current ultracentrifugation protocols are commercially unreproducible, as they produce a heterogeneous mix of exosomes, other cellular vesicles and macromolecular complexes.

In addition, siRNA loading into exosomes is relatively inefficient and cost-ineffective, highlighting the need for the development of transfection reagents tailored for nanoparticle applications.

Further, exosomes are rapidly cleared from circulation and substantially accumulate in the liver within 24 hours of administration (Ohno et al., 2013 Mol Therapy 21(1):185), limiting their application for long-term drug delivery to the circulatory of a subject.

Though effective in many cases in increasing circulation half-life, especially as the hydrodynamic radius of the graft or fusion increases (Gao, Liu, et al., 2009 PNAS 106(36):15231), these methods offer challenges in manufacturing and maintenance of biological effector function.

Heterogeneities in conjugation reactions can cause complex product mixtures with varying biological activities, due mostly to the utilization of site-unspecific chemistries.

Furthermore, attachment of large moieties, such as branched PEGs, to reactive zones of proteins can lead to decreased receptor affinity (Fishburn, 2008 J Pharm Sci 97(10):4167).

This method is complicated by the dynamics of albumin recycle by the neonatal Fc receptor (FcRn) and the use of cysteine-constrained cyclic peptides for functionality.

This may cause structural as well as manufacturing complications, e.g., because of the use of complex cyclic or large domains for functionality.

Methods of fusing larger antibody fragments may not be amendable to proteins with an already complex folding structure or low expression yield.

The development of more potent T cells is limited, however, by safety concerns, highlighted by the occurrence of on-target and off-target toxicities that, although uncommon, have been fatal on occasions.

T cells targeting differentiation antigens can be expected to also recognize nonmalignant cells that express the same antigens, resulting in adverse events.

On-target but off-tumour toxicities can be immediately life-threatening.

As T-cell therapy becomes more effective, acute toxicities have also become more evident.

Images